Related Experiment Video
Updated: Feb 19, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials
O V Markov1, N L Mironova1, V V Vlassov1
1Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva Ave. 8, Novosibirsk, 630090 , Russia.
Abstract:
The routine methods used to treat oncological diseases have a number of drawbacks, including non-specific action and severe side effects for patients. Furthermore, tumor diseases are associated with a suppression of the immune system that often leads to the inefficiency of standard treatment methods. The development of novel immunotherapeutic approaches having specific antitumor action and that activate the immune system is of crucial importance. Vaccines based on dendritic cells (DCs) loaded with tumor antigens ex vivo that can activate antitumor cytotoxic T-cell responses stand out among different antitumor immunotherapeutic approaches. This review is focused on analyzing different methods of DC-based vaccine preparation and current research in antitumor DC-based vaccines using animal tumor models and in clinical trials.
Insights
Dendritic cell (DC) vaccines offer a promising immunotherapy for cancer by activating T-cells against tumors. This review examines DC vaccine preparation methods and their effectiveness in preclinical and clinical studies.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Conventional cancer treatments often lack specificity and cause severe side effects.
- Tumor-induced immunosuppression can limit the efficacy of standard therapies.
- Novel immunotherapies are needed to specifically target cancer and boost immune responses.
Purpose of the Study:
- To review dendritic cell (DC)-based vaccine preparation methods.
- To analyze current research on antitumor DC vaccines in animal models and clinical trials.
- To highlight the potential of DC vaccines in cancer immunotherapy.
Main Methods:
- Review of scientific literature on DC vaccine development.
- Analysis of preclinical studies using animal tumor models.
- Examination of clinical trial data for DC-based cancer vaccines.
Main Results:
- Dendritic cell vaccines loaded with tumor antigens can elicit specific antitumor cytotoxic T-cell responses.
- Various ex vivo methods exist for preparing DC-based vaccines.
- Preclinical and clinical data suggest potential efficacy, though challenges remain.
Conclusions:
- Dendritic cell vaccines represent a significant approach in cancer immunotherapy.
- Further research and optimization of DC vaccine preparation are crucial.
- DC-based vaccines hold promise for overcoming tumor-induced immunosuppression and improving patient outcomes.
